ImmunoPrecise Antibodies Ltd. has forged a strategic collaboration with RIBOPRO, a pioneering technology provider specializing in mRNA and lipid nanoparticle (LNP) technologies.

This collaboration seeks to revolutionize the discovery and development of therapeutic antibodies by integrating RIBOPRO’s advanced mRNA-based antigen expression expertise with IPA’s in silico and wet-lab antibody discovery capabilities.

The collaboration leverages RIBOPRO’s expertise in mRNA sequence optimization and LNP-based delivery with IPA’s advanced B-cell screening, single-cell analysis, and deep-learning AI-driven discovery workflows. Together, the two companies aim to accelerate and enhance the development of novel therapeutics by improving antigen presentation and immune responses, a critical step in antibody discovery.

The success of generating therapeutic lead antibodies towards complex antigens using traditional immunization-based discovery platforms may be hampered by challenges associated with the proper expression of these antigens. By leveraging RIBOPRO’s proprietary mRNA and LNP technologies, this partnership enables precise, efficient antigen expression, thereby facilitating potentially more effective immune responses and possibly accelerating the path to discovering novel antibody therapeutics.

“Partnering with ImmunoPrecise Antibodies enables us to push the boundaries of mRNA-based immunization for therapeutic antibody discovery. By integrating our expertise in mRNA design and nanoparticle delivery with IPA’s cutting-edge antibody discovery and engineering capabilities, we can address longstanding challenges in antigen expression, bringing forth new possibilities for precision therapeutics,” said Sander van Asbeck, CEO of RIBOPRO.

IPA’s approach combines advanced AI-driven analytics with highly specialized wet-lab methodologies to design and optimize antibodies with the highest clinical relevance. The integration of mRNA immunization into IPA’s workflow is expected to further enhance the precision and efficiency of their antibody discovery pipeline.

“We are enthusiastic to expand our toolbox for the discovery of novel therapeutic antibodies with a state-of-the-art mRNA immunization platform in this alliance. Combining RIBOPRO’s and IPA’s unique expertise further strengthens our commitment to be at the forefront of solving complex challenges with innovative and high-quality solutions,” said Dr. Ilse Roodink, CSO of ImmunoPrecise Antibodies.